

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

NCT06815627

Status	RECRUITING
Phase	Phase 3
Sponsor	Trust Bio-sonics, Inc.
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (4)

- years of age or older
- Ability to understand and the willingness to provide written informed consent
- Having or suspected of having cardiac disease
- Undergone a transthoracic echo within 30 days prior to NH002 dose administration, resulting in suboptimal LVEBD, as defined by 2 or more segments of 6 segments of the ventricular border that cannot be visualized reliably in any of the standard apical 4-, 2-, and 3-chamber views during the resting non-contrast ultrasound examination

Exclusion (17)

- Any evidence of other severe or unstable cardiopulmonary and/or systemic hemodynamic conditions deemed unsuitable for the study by the investigator(s) prior to NH002 dose administration, including, but not limited to:
 - ongoing or recent acute coronary syndrome within 6 months.
 - uncontrolled serious ventricular arrhythmias.
 - decompensated or inadequately controlled congestive heart failure (New York Heart Association Class IV).
 - atrial fibrillation or current uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise.
- ... and 12 more (see full listing online)

Locations (6 total)

Keelung Chang Gung Memorial Hospital & Lovers Lake Branch, Keelung, Taiwan
China Medical University Hospital, Taichung, Taiwan
MacKay Memorial Hospital, Taipei, Taiwan
... and 3 more locations